Prognostic value of CT findings to predict survival outcomes in patients with pancreatic neuroendocrine neoplasms: a single institutional study of 161 patients

被引:31
|
作者
Kim, Dong Wook [1 ,2 ]
Kim, Hyoung Jung [1 ,2 ]
Kim, Kyung Won [1 ,2 ]
Byun, Jae Ho [1 ,2 ]
Kim, So Yeon [1 ,2 ]
Song, Ki Byung [3 ]
Ramaiya, Nikhil H. [4 ]
Tirumani, Sree Harsha [4 ]
Hong, Seung-Mo [5 ]
机构
[1] Univ Ulsan, Coll Med, Dept Radiol, 86 Asanbyeongwon Gil, Seoul 138736, South Korea
[2] Univ Ulsan, Coll Med, Res Inst Radiol, Asan Med Ctr, 86 Asanbyeongwon Gil, Seoul 138736, South Korea
[3] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Surg, Seoul 138736, South Korea
[4] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Imaging,Brigham & Womens Hosp, 44 Binney St, Boston, MA 02115 USA
[5] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Pathol, Seoul 138736, South Korea
关键词
Pancreas; Neuroendocrine neoplasm; Overall survival; Recurrence free survival; CT; ENDOCRINE TUMORS; MICROVASCULAR DENSITY; HELICAL CT; ADENOCARCINOMA; CLASSIFICATION; EXPRESSION; FEATURES; SYSTEM; CANCER; MDCT;
D O I
10.1007/s00330-015-3943-5
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Objectives To evaluate the prognostic value of CT to predict recurrence-free and overall survival in patients with pancreatic neuroendocrine neoplasms (PanNENs). Methods Between January 2004 and December 2012, 161 consecutive patients who underwent preoperative triphasic CT and surgical resection with curative intent for PanNENs were identified. The tumour consistency, margin, presence of calcification, pancreatic duct dilatation, bile duct dilatation, vascular invasion, and hepatic metastases were evaluated. The tumour size, arterial enhancement ratio, and portal enhancement ratio were measured. The Cox proportional hazard model was used to determine the association between CT features and recurrence-free survival and overall survival. Results By multivariate analysis, tumour size (> 3 cm) (hazard ratio, 3.314; p = 0.006), portal enhancement ratio (a parts per thousand currency sign1.1) (hazard ratio, 2.718; p = 0.006), and hepatic metastases (hazard ratio, 4.374; p = 0.003) were independent significant variables for worse recurrence-free survival. Portal enhancement ratio (a parts per thousand currency sign1.1) (hazard ratio, 5.951; p = 0.001) and hepatic metastases (hazard ratio, 4.122; p = 0.021) were independent significant variables for worse overall survival. Conclusions Portal enhancement ratio (a parts per thousand currency sign1.1) and hepatic metastases assessed on CT were common independent prognostic factors for worse recurrence-free survival and overall survival in patients with PanNENs.
引用
收藏
页码:1320 / 1329
页数:10
相关论文
共 50 条
  • [31] Incidence, survival, and prognostic factors for patients with gastrointestinal mixed neuroendocrine non-neuroendocrine neoplasms: a SEER population-based study
    Boqi Xu
    Fan Zhang
    Runda Wu
    Yao Peng
    Zhongqi Mao
    Shan Tong
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 15657 - 15669
  • [32] Trends in the incidence and survival outcomes in patients with lung neuroendocrine neoplasms in the United States.
    Gosain, Rohit
    Shah, Shrunjal
    Dasari, Arvind
    Halfdanarson, Thorvardur Ragnar
    Mukherjee, Sarbajit
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [33] Development and Validation of a Novel Machine Learning Model to Predict the Survival of Patients with Gastrointestinal Neuroendocrine Neoplasms
    Liu, Si
    Chen, Yun-Xiang
    Dai, Bing
    Chen, Li
    NEUROENDOCRINOLOGY, 2024, 114 (08) : 733 - 748
  • [34] Pancreatic metastases in patients with neuroendocrine neoplasms: A multi-centre cohort study
    Tsoli, Marina
    Daskalakis, Kosmas
    Wedin, Maria
    Angelousi, Anna
    Povlsen, Sebastian
    Srirajaskanthan, Raj
    Giovos, George
    Weickert, Martin O.
    Kogut, Angelika
    Kos-Kudla, Beata
    Oleinikov, Kira
    Grozinsky-Glasberg, Simona
    Kaltsas, Gregory
    JOURNAL OF NEUROENDOCRINOLOGY, 2023, 35 (04)
  • [35] Prognostic Value of FDG PET/CT in Patients With Neuroendocrine Carcinoma of the Uterine Cervix
    Jiang, Yuanyuan
    Hou, Guozhu
    Li, Fang
    Zhu, Zhaohui
    Cheng, Wuying
    CLINICAL NUCLEAR MEDICINE, 2021, 46 (12) : 971 - 976
  • [36] Epidemiologic trends and prognostic risk factors of patients with pancreatic neuroendocrine neoplasms in the US: an updated population-based study
    Lu, Lili
    Shang, Yuru
    Mullins, Christina Susanne
    Zhang, Xianbin
    Linnebacher, Michael
    FUTURE ONCOLOGY, 2021, 17 (05) : 549 - 563
  • [37] Changes in Survival Outcomes of Patients With Neuroendocrine Neoplasms Over the Past 15 Years A Real-World Study
    Abdel-Rahman, Omar
    Pham, Truong-Minh
    Pokhrel, Arun
    Ruether, Dean
    Sawyer, Michael B.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2022, 45 (05): : 208 - 214
  • [38] The application of the Glasgow prognostic score to predict the survival in patients with metastatic pancreatic carcinoma
    Mohammed, Amrallah A.
    Al-Zahrani, Omar
    Elsayed, Fifi Mostafa
    INDIAN JOURNAL OF PALLIATIVE CARE, 2022, 28 (04) : 406 - 412
  • [39] Prognostic factors and survival in 144 patients with gastro-entero-pancreatic neuroendocrine tumors
    Panzuto, F
    Nasoni, S
    Cattaruzza, MS
    Milione, M
    Cassetta, S
    Tornatore, V
    Di Fonzo, M
    Capurso, G
    Corleto, VD
    Bordi, C
    Delle Fave, G
    GASTROENTEROLOGY, 2004, 126 (04) : A391 - A392
  • [40] Prognostic value of 18FDG PET/CT volumetric parameters in the survival prediction of patients with pancreatic cancer
    Mohamed, Eyas
    Needham, Alexander
    Psarelli, Eftychia
    Carroll, Melvyn
    Vinjamuri, Sobhan
    Sanghera, Bal
    Wong, Wai Lup
    Halloran, Christopher
    Ghaneh, Paula
    EJSO, 2020, 46 (08): : 1532 - 1538